A Research Study Looking at the Safety of Multiple Doses of ZP8396 and How it Works in the Body of Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

November 7, 2022

Primary Completion Date

June 13, 2024

Study Completion Date

June 13, 2024

Conditions
OverweightHealthy VolunteersObese
Interventions
DRUG

ZP8396

"Part 1: Participants will receive 6 once-weekly doses of ZP8396 given subcutaneously (s.c., under the skin). Dose level will depend on the cohort.~Part 2: Participants will receive 16 once-weekly doses of ZP8396 given subcutaneously (s.c., under the skin). Dose level will depend on the cohort. Dose up-titration will be used."

DRUG

Drug: Placebo (ZP8396)

"Part 1: Participants will receive 6 once-weekly doses of placebo given subcutaneously (s.c., under the skin).~Part 2: Participants will receive 16 once-weekly doses of placebo given subcutaneously (s.c., under the skin)."

Trial Locations (1)

41460

Profil Institut für Stoffwechselforschung GmbH, Neuss

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Zealand Pharma

INDUSTRY